In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Morbidity and mortality in patients precluded for transvenous pacemaker implantation: Experience with the Micra transcatheter pacemaker

Session Top of the pops in arrhythmia treatment - from life-style modification to lead extraction

Speaker Jayanthi Koneru

Event : ESC Congress 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Device Complications and Lead Extraction
  • Session type : Abstract Sessions

Authors : A Garg (Richmond,US), JN Koneru (Richmond,US), D Fagan (Mounds View, Minnesota,US), K Stromberg (Mounds View, Minnesota,US), MF El-Chami (Atlanta,US), JP Piccini (Durham,US), PR Roberts (Southampton,GB), K Soejima (Tokyo,JP), A Cheng (Mounds View, Minnesota,US), KA Ellenbogen (Richmond,US)

A. Garg1 , J.N. Koneru1 , D. Fagan2 , K. Stromberg2 , M.F. El-Chami3 , J.P. Piccini4 , P.R. Roberts5 , K. Soejima6 , A. Cheng2 , K.A. Ellenbogen1 , 1Virginia Commonwealth University - Richmond - United States of America , 2Medtronic - Mounds View, Minnesota - United States of America , 3Emory University - Atlanta - United States of America , 4Duke Clinical Research Institute - Durham - United States of America , 5University Hospital Southampton NHS Foundation Trust - Southampton - United Kingdom , 6Kyorin University - Tokyo - Japan ,

Device Complications and Lead Extraction

European Heart Journal ( 2019 ) 40 ( Supplement ), 3652

Background: The Micra transcatheter pacemaker has proven to be a safe and effective alternative to transvenous pacemakers (TVPs). However, the safety profile after Micra implantation in patients deemed poor candidates for TVPs is poorly understood.

Purpose: To evaluate the safety and all-cause mortality outcomes in Micra recipients stratified by whether or not they were precluded for therapy with TVP.

Methods: Micra patients from the Micra Transcatheter Pacing (IDE) Study, Continued Access (CA) study, and Post-Approval Registry (PAR) were divided into groups based upon whether or not the implanting physician considered the patient to be precluded from receiving a transvenous pacing system. All-cause mortality was compared between the Micra patient groups and patients receiving a single-chamber transvenous pacing system (SC-TVP) since 2010 from the Medtronic product surveillance registry using univariate and multivariate Cox models.

Results: Among 2,819 patients who underwent a Micra implant attempt, the overall major complication rate through 24 months was 3.5%. In these patients, 548 were deemed precluded from TVP implantation. Prior device infection or bacteremia (38.9%), venous access issues (36.1%) and thrombosis (10.2%) were amongst the most common causes of preclusion for TVP implantation. These patients were younger (71.7 vs. 76.7 years), more frequently on hemodialysis (26.3% vs. 2.5%), and more often had a prior CIED implanted (38.4% vs. 4.4%) than non-precluded patients. Over an average follow-up of 13.5±11.1 months, all-cause mortality was significantly higher in precluded Micra patients compared with SC-TVP patients (HR: 2.16, 95% CI: 1.54–3.2, P<0.001) (Figure 1). However, there was no significant difference in all-cause mortality when comparing non-precluded Micra patients and SC-TVP patients (HR: 1.12, 95% CI: 0.86–1.44, P=0.401). Acute all-cause death (within 1 month) among Micra patients was 2.74% and 1.32% in the precluded and non-precluded TVP groups, respectively. The procedure-related death rate was 0.55% for the TVP precluded group and 0.13% for the not precluded group (P=0.092). The major complication rate through 24-months was similar between the two Micra groups (4.0% vs 3.4%, P=0.630).

Conclusion: The overall safety profile of Micra remains is in line with previously reported data. All-cause mortality risk (both acute and long term) appears to be higher in patients who were precluded from receiving TVP.

All-cause mortality for Micra and SC-TVP

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are